Literature DB >> 21691062

The electrophysiological effects of cardiac glycosides in human iPSC-derived cardiomyocytes and in guinea pig isolated hearts.

Liang Guo1, Jian-Yong Qian, Rory Abrams, Hai-Ming Tang, Thomas Weiser, Martin J Sanders, Kyle L Kolaja.   

Abstract

BACKGROUND/AIMS: Monitoring changes in the field potential (FP) of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) following compound administration has been proposed as a novel screening tool to evaluate cardiac ion channel interactions and QT liability. Here we extended the use of FP to evaluate the pharmacological and toxicological properties of cardiac glycosides.
METHODS: FPs were recorded using microelectrode arrays (MEAs) in spontaneously beating hiPSC-CMs. The in vitro effects of ouabain and digoxin on FPs were compared with data generated on hemodynamic and ECG parameters in guinea pig Langendorff hearts.
RESULTS: In hiPSC-CMs, ouabain and digoxin reduced Na(+)-spike amplitude, shortened FP duration (FPD), increased Ca(2+)-wave amplitude, and dose-dependently induced arrhythmic beats. The ouabain-induced changes observed in hiPSC-CMs correlated well with the effects seen in isolated hearts which revealed QT shortening, enhancement of contractility, and arrhythmogenesis. Nifedipine, an L-type Ca(2+) channel blocker, reduced Ca(2+)-wave amplitude and FPD in hiPSC-CMs, and led to parallel effects of decreased ventricular contractility and shortened QT interval in isolated hearts. Further, nifedipine attenuated the Ca(2+)-peak amplitude and proarrhythmic effect of both glycosides. These results suggested that FPD and Ca(2+)-wave amplitude are comparable surrogates of QT interval and contractility of intact hearts, respectively.
CONCLUSION: hiPSC-CMs reflect similar cardiac pharmacology as seen in isolated cardiac preparations and thus are a suitable model in study of the pharmacology and toxicology of cardioactive ion channel and transporter modulators.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21691062     DOI: 10.1159/000329966

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  19 in total

Review 1.  Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues.

Authors:  Nicole T Feric; Milica Radisic
Journal:  Adv Drug Deliv Rev       Date:  2015-05-05       Impact factor: 15.470

2.  Microfluidic heart on a chip for higher throughput pharmacological studies.

Authors:  Ashutosh Agarwal; Josue Adrian Goss; Alexander Cho; Megan Laura McCain; Kevin Kit Parker
Journal:  Lab Chip       Date:  2013-09-21       Impact factor: 6.799

Review 3.  Induced Pluripotent Stem Cell Models to Enable In Vitro Models for Screening in the Central Nervous System.

Authors:  Joshua G Hunsberger; Anastasia G Efthymiou; Nasir Malik; Mamta Behl; Ivy L Mead; Xianmin Zeng; Anton Simeonov; Mahendra Rao
Journal:  Stem Cells Dev       Date:  2015-04-20       Impact factor: 3.272

Review 4.  High throughput physiological screening of iPSC-derived cardiomyocytes for drug development.

Authors:  Juan C Del Álamo; Derek Lemons; Ricardo Serrano; Alex Savchenko; Fabio Cerignoli; Rolf Bodmer; Mark Mercola
Journal:  Biochim Biophys Acta       Date:  2016-03-04

Review 5.  Cardiomyocytes derived from human induced pluripotent stem cells as models for normal and diseased cardiac electrophysiology and contractility.

Authors:  Adriana Blazeski; Renjun Zhu; David W Hunter; Seth H Weinberg; Elias T Zambidis; Leslie Tung
Journal:  Prog Biophys Mol Biol       Date:  2012-08-07       Impact factor: 3.667

Review 6.  Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as Models for Cardiac Channelopathies: A Primer for Non-Electrophysiologists.

Authors:  Priyanka Garg; Vivek Garg; Rajani Shrestha; Michael C Sanguinetti; Timothy J Kamp; Joseph C Wu
Journal:  Circ Res       Date:  2018-07-06       Impact factor: 17.367

Review 7.  Electrophysiological and contractile function of cardiomyocytes derived from human embryonic stem cells.

Authors:  Adriana Blazeski; Renjun Zhu; David W Hunter; Seth H Weinberg; Kenneth R Boheler; Elias T Zambidis; Leslie Tung
Journal:  Prog Biophys Mol Biol       Date:  2012-08-07       Impact factor: 3.667

Review 8.  The case for induced pluripotent stem cell-derived cardiomyocytes in pharmacological screening.

Authors:  Jaffar M Khan; Alexander R Lyon; Sian E Harding
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

9.  Phytochemical analysis and in-vitro anti-African swine fever virus activity of extracts and fractions of Ancistrocladus uncinatus, Hutch and Dalziel (Ancistrocladaceae).

Authors:  Folorunso O Fasina; Oyinlola O Olaokun; Olusola O Oladipo; Margaret M Fasina; Adesoji A Makinde; Livio Heath; Armanda D S Bastos
Journal:  BMC Vet Res       Date:  2013-06-19       Impact factor: 2.741

Review 10.  Current status of drug screening and disease modelling in human pluripotent stem cells.

Authors:  Divya Rajamohan; Elena Matsa; Spandan Kalra; James Crutchley; Asha Patel; Vinoj George; Chris Denning
Journal:  Bioessays       Date:  2012-08-08       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.